Clinical Trial

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-12-20; most recent amendment 2026-03-03.
Status change: Not Yet Recruiting → Recruiting 2022-05-19
Trial Details
NCT Number NCT05181735
Lead Sponsor Groupe Francophone des Myelodysplasies
Collaborators: Celgene
Conditions MDS, Myelodysplastic Syndromes
Enrollment 150 participants
Start Date 2022-05-18
Primary Completion 2028-12-19 (estimated)
Study Completion 2029-06-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-05